{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:06:29Z","timestamp":1791223589890,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22Y21900100"],"award-info":[{"award-number":["22Y21900100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072951"],"award-info":[{"award-number":["82072951"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017633","name":"Shanghai Anticancer Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017633","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although anaplastic thyroid cancer (ATC) constitutes only 1\u20132% of all thyroid malignancies, it is associated with an exceptionally high mortality rate, accounting for 14\u201339% of thyroid cancer-related deaths. In this study, we identified the critical role of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) in ATC progression. Proteomic analysis revealed E-cadherin as a key mediator of PCSK9-driven malignancy in ATC. Mechanistically, PCSK9 promotes the degradation of E-cadherin through the lysosomal pathway. Furthermore, the loss of the p53 function, particularly the R248Q mutation, de-repressed\n                    <jats:italic>PCSK9<\/jats:italic>\n                    expression at the transcriptional level. Notably, the PCSK9 inhibitor PF-846 considerably suppressed ATC proliferation and metastasis in both in vitro and in vivo models. In conclusion, PCSK9 enhances ATC malignancy by regulating E-cadherin degradation via the lysosomal pathway, underscoring its potential as a promising therapeutic target.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-07690-1","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:06:27Z","timestamp":1746489987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["PCSK9 promotes progression of anaplastic thyroid cancer through E-cadherin endocytosis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-0143","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2941-2599","authenticated-orcid":false,"given":"Linkun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6110-8844","authenticated-orcid":false,"given":"Jun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"7690_CR1","first-page":"363","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA: A Cancer J Clin. 2019;69:363\u201385.","journal-title":"CA: A Cancer J Clin"},{"key":"7690_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41574-019-0263-x","volume":"16","author":"J Kim","year":"2020","unstructured":"Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16:17\u201329.","journal-title":"Nat Rev Endocrinol"},{"key":"7690_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"Boucai L, Zafereo M, Cabanillas ME. Thyroid cancer: a review. JAMA. 2024;331:425\u201335.","journal-title":"JAMA"},{"key":"7690_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8428547","volume":"2019","author":"NS Huang","year":"2019","unstructured":"Huang NS, Shi X, Lei BW, Wei WJ, Lu ZW, Yu PC, et al. An update of the appropriate treatment strategies in anaplastic thyroid cancer: a population-based study of 735 patients. Int J Endocrinol. 2019;2019:8428547.","journal-title":"Int J Endocrinol"},{"key":"7690_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol. 2020;6:1397\u2013404.","journal-title":"JAMA Oncol"},{"key":"7690_CR6","first-page":"259","volume":"30","author":"S Hamidi","year":"2023","unstructured":"Hamidi S, Maniakas A. Recent advances in anaplastic thyroid cancer management. Curr Opin Endocrinol, Diab, Obes. 2023;30:259\u201364.","journal-title":"Curr Opin Endocrinol, Diab, Obes"},{"key":"7690_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ecl.2021.11.020","volume":"51","author":"A Maniakas","year":"2022","unstructured":"Maniakas A, Zafereo M, Cabanillas ME. Anaplastic thyroid cancer: new horizons and challenges. Endocrinol Metab Clin North Am. 2022;51:391\u2013401.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"7690_CR8","doi-asserted-by":"publisher","first-page":"101678","DOI":"10.1016\/j.beem.2022.101678","volume":"37","author":"SN Rao","year":"2023","unstructured":"Rao SN, Smallridge RC. Anaplastic thyroid cancer: an update. Best Pr Res Clin Endocrinol Metab. 2023;37:101678.","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"key":"7690_CR9","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1172\/JCI120966","volume":"128","author":"JA Knauf","year":"2018","unstructured":"Knauf JA, Luckett KA, Chen KY, Voza F, Socci ND, Ghossein R, et al. Hgf\/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. J Clin Investig. 2018;128:4086\u201397.","journal-title":"J Clin Investig"},{"key":"7690_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154\u20136.","journal-title":"Nat Genet"},{"key":"7690_CR11","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1086\/302370","volume":"64","author":"M Varret","year":"1999","unstructured":"Varret M, Rab\u00e8s JP, Saint-Jore B, Cenarro A, Marinoni JC, Civeira F, et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet. 1999;64:1378\u201387.","journal-title":"Am J Hum Genet"},{"key":"7690_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/01.ATV.20.4.1089","volume":"20","author":"SC Hunt","year":"2000","unstructured":"Hunt SC, Hopkins PN, Bulka K, McDermott MT, Thorne TL, Wardell BB, et al. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arteriosclerosis Thrombosis Vasc Biol. 2000;20:1089\u201393.","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"7690_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1161\/CIRCRESAHA.118.313648","volume":"124","author":"S Spolitu","year":"2019","unstructured":"Spolitu S, Okamoto H, Dai W, Zadroga JA, Wittchen ES, Gromada J, et al. Hepatic glucagon signaling regulates PCSK9 and low-density lipoprotein cholesterol. Circ Res. 2019;124:38\u201351.","journal-title":"Circ Res"},{"key":"7690_CR14","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/j.jacc.2017.08.057","volume":"70","author":"A Bayes-Genis","year":"2017","unstructured":"Bayes-Genis A, N\u00fa\u00f1ez J, Zannad F, Ferreira JP, Anker SD, Cleland JG, et al. The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. J Am Coll Cardiol. 2017;70:2128\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"7690_CR15","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.7150\/ijbs.81415","volume":"19","author":"W Jin","year":"2023","unstructured":"Jin W, Yu J, Su Y, Lin H, Liu T, Chen J, et al. Drug repurposing flubendazole to suppress tumorigenicity via PCSK9-dependent inhibition and potentiate lenvatinib therapy for hepatocellular carcinoma. Int J Biol Sci. 2023;19:2270\u201388.","journal-title":"Int J Biol Sci"},{"key":"7690_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31663-z","volume":"13","author":"CC Wong","year":"2022","unstructured":"Wong CC, Wu JL, Ji F, Kang W, Bian X, Chen H, et al. The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC\/KRAS-mutant colorectal cancer. Nat Commun. 2022;13:3971.","journal-title":"Nat Commun"},{"key":"7690_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693\u20138.","journal-title":"Nature"},{"key":"7690_CR18","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","volume":"10","author":"ME Cabanillas","year":"2024","unstructured":"Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B. et al. Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial. JAMA Oncology. 2024;10:1672\u201380.","journal-title":"JAMA Oncology"},{"key":"7690_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1089\/thy.2024.0090","volume":"34","author":"F Pitoia","year":"2024","unstructured":"Pitoia F, Abelleira E, Rom\u00e1n-Gonz\u00e1lez A, Danilovic DLS, Scheffel RS, Maia AL, et al. Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary latin American experience. Thyroid : J Am Thyroid Assoc. 2024;34:949\u201352.","journal-title":"Thyroid : J Am Thyroid Assoc"},{"key":"7690_CR20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid : J Am Thyroid Assoc. 2021;31:1076\u201385.","journal-title":"Thyroid : J Am Thyroid Assoc"},{"key":"7690_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1089\/thy.2022.0597","volume":"33","author":"A Iesato","year":"2023","unstructured":"Iesato A, Li S, Sadow PM, Abbasian M, Nazarian A, Lawler J, et al. The tyrosine kinase inhibitor lenvatinib inhibits anaplastic thyroid carcinoma growth by targeting pericytes in the tumor microenvironment. Thyroid : J Am Thyroid Assoc. 2023;33:835\u201348.","journal-title":"Thyroid : J Am Thyroid Assoc"},{"key":"7690_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10555-008-9179-y","volume":"28","author":"O Schmalhofer","year":"2009","unstructured":"Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151\u201366.","journal-title":"Cancer Metastasis Rev"},{"key":"7690_CR23","doi-asserted-by":"publisher","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","volume":"284","author":"S Poirier","year":"2009","unstructured":"Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009;284:28856\u201364.","journal-title":"J Biol Chem"},{"key":"7690_CR24","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Investig. 2016;126:1052\u201366.","journal-title":"J Clin Investig"},{"key":"7690_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol : J Eur Soc Med Oncol. 2022;33:406\u201315.","journal-title":"Ann Oncol : J Eur Soc Med Oncol"},{"key":"7690_CR26","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1200\/JCO.20.03093","volume":"39","author":"LJ Wirth","year":"2021","unstructured":"Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, et al. Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol: J Am Soc Clin Oncol. 2021;39:2359\u201366.","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"7690_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/ncb3136","volume":"17","author":"T Lecuit","year":"2015","unstructured":"Lecuit T, Yap AS. E-cadherin junctions as active mechanical integrators in tissue dynamics. Nat cell Biol. 2015;17:533\u20139.","journal-title":"Nat cell Biol"},{"key":"7690_CR28","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1038\/s41388-018-0304-2","volume":"37","author":"AM Mendonsa","year":"2018","unstructured":"Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer. Oncogene. 2018;37:4769\u201380.","journal-title":"Oncogene"},{"key":"7690_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/hep.29798","volume":"68","author":"M Lu","year":"2018","unstructured":"Lu M, Wu J, Hao ZW, Shang YK, Xu J, Nan G, et al. Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress. Hepatol (Balt, Md). 2018;68:317\u201332.","journal-title":"Hepatol (Balt, Md)"},{"key":"7690_CR30","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/cas.15341","volume":"113","author":"S Zhang","year":"2022","unstructured":"Zhang S, He Y, Xuan Q, Ling X, Men K, Zhao X, et al. TMEM139 prevents NSCLC metastasis by inhibiting lysosomal degradation of E-cadherin. Cancer Sci. 2022;113:1999\u20132007.","journal-title":"Cancer Sci"},{"key":"7690_CR31","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1080\/15548627.2020.1734330","volume":"16","author":"CS Evans","year":"2020","unstructured":"Evans CS, Holzbaur ELF. Lysosomal degradation of depolarized mitochondria is rate-limiting in OPTN-dependent neuronal mitophagy. Autophagy. 2020;16:962\u20134.","journal-title":"Autophagy"},{"key":"7690_CR32","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1021\/acs.jmedchem.0c01689","volume":"64","author":"J Pei","year":"2021","unstructured":"Pei J, Wang G, Feng L, Zhang J, Jiang T, Sun Q, et al. Targeting lysosomal degradation pathways: new strategies and techniques for drug discovery. J Med Chem. 2021;64:3493\u2013507.","journal-title":"J Med Chem"},{"key":"7690_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41568-023-00574-6","volume":"23","author":"B Banushi","year":"2023","unstructured":"Banushi B, Joseph SR, Lum B, Lee JJ, Simpson F. Endocytosis in cancer and cancer therapy. Nat Rev Cancer. 2023;23:450\u201373.","journal-title":"Nat Rev Cancer"},{"key":"7690_CR34","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.tcb.2019.08.008","volume":"29","author":"M Savini","year":"2019","unstructured":"Savini M, Zhao Q, Wang MC. Lysosomes: signaling hubs for metabolic sensing and longevity. Trends cell Biol. 2019;29:876\u201387.","journal-title":"Trends cell Biol"},{"key":"7690_CR35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2216796120","volume":"120","author":"Q Zhu","year":"2023","unstructured":"Zhu Q, Wang H, Chai S, Xu L, Lin B, Yi W, et al. O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation. Proc Natl Acad Sci USA. 2023;120:e2216796120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7690_CR36","doi-asserted-by":"crossref","unstructured":"Luo H, Xia X, Kim GD, Liu Y, Xue Z, Zhang L, et al. Characterizing dedifferentiation of thyroid cancer by integrated analysis. Sci Adv. 2021;7.","DOI":"10.1126\/sciadv.abf3657"},{"key":"7690_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg7125","volume":"9","author":"P Yu","year":"2023","unstructured":"Yu P, Qu N, Zhu R, Hu J, Han P, Wu J, et al. TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Sci Adv. 2023;9:eadg7125.","journal-title":"Sci Adv"},{"key":"7690_CR38","doi-asserted-by":"crossref","unstructured":"Manzella L, Stella S, Pennisi MS, Tirr\u00f2 E, Massimino M, Romano C, et al. New insights in thyroid cancer and p53 family proteins. Int J Mol Sci. 2017;18.","DOI":"10.3390\/ijms18061325"},{"key":"7690_CR39","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12020-016-1080-9","volume":"54","author":"S Latteyer","year":"2016","unstructured":"Latteyer S, Tiedje V, K\u00f6nig K, Ting S, Heukamp LC, Meder L, et al. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine. 2016;54:733\u201341.","journal-title":"Endocrine"},{"key":"7690_CR40","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu Y, Su Z, Tavana O, Gu W. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell. 2024;42:946\u201367.","journal-title":"Cancer Cell"},{"key":"7690_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev-med-042716-091351","volume":"69","author":"CN Hess","year":"2018","unstructured":"Hess CN, Low Wang CC, Hiatt WR. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annu Rev Med. 2018;69:133\u201345.","journal-title":"Annu Rev Med"},{"key":"7690_CR42","doi-asserted-by":"publisher","first-page":"108480","DOI":"10.1016\/j.pharmthera.2023.108480","volume":"249","author":"S Hummelgaard","year":"2023","unstructured":"Hummelgaard S, Vilstrup JP, Gustafsen C, Glerup S, Weyer K. Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther. 2023;249:108480.","journal-title":"Pharmacol Ther"},{"key":"7690_CR43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","volume":"12","author":"J Yuan","year":"2021","unstructured":"Yuan J, Cai T, Zheng X, Ren Y, Qi J, Lu X, et al. Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. Protein Cell. 2021;12:240\u201360.","journal-title":"Protein Cell"},{"key":"7690_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, et al. Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9:13.","journal-title":"Signal Transduct Target Ther"},{"key":"7690_CR45","doi-asserted-by":"publisher","first-page":"e2001882","DOI":"10.1371\/journal.pbio.2001882","volume":"15","author":"NG Lintner","year":"2017","unstructured":"Lintner NG, McClure KF, Petersen D, Londregan AT, Piotrowski DW, Wei L, et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol. 2017;15:e2001882.","journal-title":"PLoS Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07690-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T01:02:35Z","timestamp":1746493355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07690-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7690"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07690-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experimental procedures received approval from the FUSCC animal experimentation ethics committee. And all methods were performed in accordance with the relevant guidelines and regulations of the Basel Declaration. and the study was reported following ARRIVE guidelines. All procedures involving human participants were conducted in compliance with the Ethical Committee of Fudan University Shanghai Cancer Center (050432-4-2307E) and in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent for publication was obtained from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"362"}}